A recent report published by Infinium Global Research on the transcatheter mitral valve replacement market provides in-depth analysis of segments and sub-segments in the global as well as regional transcatheter mitral valve replacement market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional transcatheter mitral valve replacement market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast, and dollar values of the global transcatheter mitral valve replacement market. According to the report, the global transcatheter mitral valve replacement market is projected to grow at a CAGR of 27% over the forecast period of 2022-2028.

Market Insight

The revenue generated by the market was approximately USD 1.4 billion in 2022 and is expected to reach approximately USD 6 billion in 2028. and is expected to grow with a CAGR of more than 27% by 2028. The mitral valve, also known as the bicuspid valve or left atrioventricular valve, is a dual-flap valve in the heart that lies between the left atrium and the left ventricle. The mitral valve and the tricuspid valve are known collectively as the atrioventricular valves because they lie between the atria and the ventricles of the heart. The mitral valve manages blood flow between the left atrium and left ventricle, and prevents the backward flow of the blood into the left atrium. Mitral regurgitation is the leakage of blood backward through the mitral valve each time the left ventricle contracts. This is the most common mitral valve disorder that causes abnormal blood flow. As a remedy for this problem, surgeons use mitral surgical valve repair procedures or transcatheter replacement meth

Coronavirus disease 2019 (COVID-19) is a global epidemic that has caused resources to be diverted to the front lines and elective surgeries like transcatheter mitral valve replacement to be postponed. The hospitals were concentrated on attending the covid-19 patients and surgical centers were closed due to the imposition of the lockdowns. Thus, there was a serious decline in the number of transcatheter mitral valve replacement surgeries. This, in turn negatively affected the market. Furthermore, stringent regulations during the covid-19 pandemic also limited the capacity of the doctors to perform surgical procedures. Supply chain disruptions affected the availability of mitral valve replacements. The market is returning to normalcy as the coivd-19 restrictions are being lifted.  Some of the key driving factors attributing to the growth of this market include an increasing number of patients with mitral valve disorders. According to a Community Cohort Study published in the online journal ‘National Library of Medicine’ in 2018, there is expected to be 2.3 million people suffering from heart valve disorders by 2030. This creates a huge opportunity for the global transcatheter mitral valve replacement market. In addition, increasing adoption of minimally invasive procedures over traditional surgical open heart procedures, reduction in hospital stays, low risk of infection, and minimal blood loss are further propelling the market. According to the world health organization (WHO), it has been estimated that the number of people suffering from cardiovascular diseases will increase to 22.2 million by 2030. The market for TMVR is expected to reach around USD 3.0 billion by 2022. However, there are certain restraining factors that could hamper the growth of this market, which include, high costs associated with the LMVD implantation compared to other therapies available for CVD diseases. New opportunities are expected to rise as the healthcare ecosystem in developing countries is growing rapidly.

Geographically, North America is expected to be the dominating region in the market over the forecast period. Asia-Pacific is expected to be the fastest-growing region in the market.  There are expected to be around 2.3 people in the United States suffering from heart valve diseases by 2030 according to a cohort community study published in the online journal ‘National Library of Medicine’ in 2018. The high prevalence of people suffering from heart valve diseases and disorders is expected to create a huge demand for mitral valve replacements in the near future. Also, the healthcare facilities from where these treatments can be accessed are also high in North America. Furthermore, the growing accessibility to healthcare in Asia-Pacific is expected to make the region the fastest growing in the world.

Segment Covered

The report on the global transcatheter mitral valve replacement market covers segments such as product and end-user. On the basis of product, the sub-markets include transapical implantation and transfemoral implantation. On the basis of end-user, the sub-markets include hospitals, sugrical centers, clinics, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Medtronic Plc, Abbott Laboratories, Edward Lifesciences Incorporation, Micro Interventional Devices, Neovasc, Biotronik SE & Co. KG, Colibri Heart Valve, Llc., Livanova Plc, Neochord Inc., and Coramaze Technologies Gmbh.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the transcatheter mitral valve replacement market. Moreover, the study highlights current market trends and provides forecast from 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.